Europäische Union - Deutsch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. anfänge der immunität wurden eine woche nach der grundimmunisierung für rhinotracheitis, calicivirus, chlamydophila felis und panleukopenie nachgewiesen. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europäische Union - Deutsch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europäische Union - Deutsch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europäische Union - Deutsch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Europäische Union - Deutsch - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. anfänge der immunität wurden 1 woche nach der grundimmunisierung für rhinotracheitis, calicivirus und chlamydophila felis nachgewiesen. die dauer der immunität beträgt 1 jahr nach der letzten (re-) impfung.

Schweiz - Deutsch - Tierarzneimittel Kompendium der Schweiz (Institut für Veterinärpharmakologie und toxikologie)

virbac (switzerland) ag - feline calicivirus (fcv), strain f9, live attenuated, feline rhinotracheitis virus (herpesvirus fhv), strain f2, live attenuated, feline panleukopenia virus, strain lr 72, live attenuated, purified p45 felv surface antigen - lyophilisat und suspension zur herstellung einer injektionssuspension für katzen - praeparatio cryodesiccata: feline calicivirus (fcv), strain f9, live attenuated 10^4.6 - 10^6.1 u., feline rhinotracheitis virus (herpesvirus fhv), strain f2, live attenuated 10^5.0-10^6.6 u., feline panleukopenia virus, strain lr 72, live attenuated 10^3.7-10^4.5 u., gelatina, kalii hydroxidum, lactosum monohydricum, acidum glutamicum, kalii dihydrogenophosphas, dikalii phosphas anhydricus, pro vitro. suspension: purified p45 felv surface antigen mind. 102 µg, aluminii hydroxidatum gelatum 1 mg, quillaja saponariae molina extractum purificatum 10 µg, natrii chloridum, aqua ad iniectabile, dinatrii phosphas, kalii dihydrogenophosphas, ad suspensionem pro 1 ml. - attenuierter lebendimpfstoff gegen felines parvo-, rhinotracheitis- und calicivirus und inaktivierter impfstoff gegen felines leukämievirus bei katzen - impfstoffe

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

intervet deutschland gmbh (3067358) - felines calicivirus, stamm f9, lebend; felines rhinotracheitisvirus, stamm g2620a, lebend; felines panleukopenievirus, stamm mw-1, lebend - lyophilisat und lösungsmittel zur herstellung einer injektionssuspension - felines calicivirus, stamm f9, lebend (35276) 0,6628 pocken- und plaque-bildende einheit; felines rhinotracheitisvirus, stamm g2620a, lebend (35302) 0,716 pocken- und plaque-bildende einheit; felines panleukopenievirus, stamm mw-1, lebend (35297) 0,6335 gewebekultur-infektiöse-dosis 50% - katze

Schweiz - Deutsch - Tierarzneimittel Kompendium der Schweiz (Institut für Veterinärpharmakologie und toxikologie)

msd animal health gmbh - felines herpesvirus (fhv-1), strain g2620a, live attenuated, feline calicivirus (fcv), strain f9, live attenuated - lyophilisat zur herstellung einer injektionssuspension für katzen - felines herpesvirus (fhv-1), strain g2620a, live attenuated ≥ 10^4.8 u., feline calicivirus (fcv), strain f9, live attenuated ≥ 10^4.6 u., gelatina, dinatrii phosphas, natrii dihydrogenophosphas, saccharum, aqua ad iniectabile, pro vitro. - attenuierter lebendimpfstoff gegen felines rhinotracheitis- und calicivirus bei katzen - impfstoffe

Schweiz - Deutsch - Tierarzneimittel Kompendium der Schweiz (Institut für Veterinärpharmakologie und toxikologie)

msd animal health gmbh - felines herpesvirus (fhv-1), strain g2620a, live attenuated, feline calicivirus (fcv), strain f9, live attenuated, feline panleukopenia virus (fpv), live attenuated, strain mw-1 - lyophilisat zur herstellung einer injektionssuspension für katzen - felines herpesvirus (fhv-1), strain g2620a, live attenuated ≥10^5.2 u., feline calicivirus (fcv), strain f9, live attenuated ≥10^4.6 u., feline panleukopenia virus (fpv), live attenuated, strain mw-1 ≥10^4.3 u., gelatina hydrolysata, sorbitolum, caseinum hydrolysatum, dinatrii phosphas dihydricus, pro vitro. - attenuierter lebendimpfstoff gegen felines rhinotracheitis-, calici- und parvovirus bei katzen - impfstoffe

Schweiz - Deutsch - Tierarzneimittel Kompendium der Schweiz (Institut für Veterinärpharmakologie und toxikologie)

boehringer ingelheim (schweiz) gmbh - feline rhinotracheitis virus (herpesvirus fhv), strain f2, live attenuated, feline calicivirus antigens (fcv), strains 431 and g1, inactivated - lyophilisat und lösungsmittel zur herstellung eine injektionssuspension für katzen - praeparatio cryodesiccata: feline rhinotracheitis virus (herpesvirus fhv), strain f2, live attenuated 10^4.9 - 10^6.2 u., feline calicivirus antigens (fcv), strains 431 and g1, inactivated 2.0 - 3.3 u., saccharum, sorbitolum, dextranum 40, caseinum hydrolysatum, collagenum hydrolysatum, dikalii phosphas anhydricus, kalii dihydrogenophosphas, kalii hydroxidum, natrii chloridum, dinatrii phosphas, pro vitro, residui: gentamicinum. i) lösungsmittel 0.5 ml: aqua ad iniectabile, ad solutionem pro 0.5 ml. ii) lösungsmittel 1 ml: aqua ad iniectabile, ad solutionem pro 1 ml. - attenuierter lebendimpfstoff gegen felines rhinotracheitisvirus mit antigenen des inaktiverten felinen calicivirus bei katzen - impfstoffe